Amicus Therapeutics Inc (FOLD)Healthcare | Biotechnology | Princeton, United States |
USD
|
Hot Take ↕ | July 11, 2026, 8:25 a.m. UTC
The investment case for Amicus Therapeutics has fundamentally collapsed due to the completed acquisition by BioMarin. While the stock recently rallied to meet the $14.50 target price, this was a merger arbitrage play rather than a sign of organic business strength. The company is now delisting, meaning the independent equity story is dead. Fundamentally, the business is deteriorating with a trailing EPS of -$0.09, negative earnings growth of nearly 96%, and a massive debt load relative to equity. The price history confirms this structural weakness, showing two consecutive years of significant declines (-13% and -42%) despite a modest cumulative gain over the last nine years, indicating the market has priced in severe future challenges. With no dividend history and a 'Hold' recommendation from analysts who likely view the remaining standalone value as negligible post-acquisition, there is no rationale for holding the stock as an independent investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.008017 |
| AutoARIMA | 0.008017 |
| AutoTheta | 0.010113 |
| MSTL | 0.016202 |
| MSTL_126 | 0.043067 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 11.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.115 |
| Excess Kurtosis | -1.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 161.304 |
| Revenue per Share | 2.057 |
| Market Cap | 4,549,870,080 |
| Forward P/E | 17.69 |
| Beta | 0.48 |
| Profit Margins | -4.28% |
| Website | https://amicusrx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2189894 |
| Address1 | 47 Hulfish Street |
| All Time High | 25.39 |
| All Time Low | 1.77 |
| Ask | 14.5 |
| Ask Size | 2,900 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 2,887,710 |
| Average Volume | 3,915,753 |
| Average Volume10Days | 2,887,710 |
| Beta | 0.481 |
| Bid | 14.48 |
| Bid Size | 2,200 |
| Board Risk | 3 |
| Book Value | 0.882 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | United States |
| Currency | USD |
| Current Price | 14.49 |
| Current Ratio | 2.843 |
| Date Short Interest | 1,776,211,200 |
| Day High | 14.5 |
| Day Low | 14.49 |
| Debt To Equity | 161.304 |
| Earnings Growth | -0.955 |
| Earnings Quarterly Growth | -0.885 |
| Ebitda | 41,951,000 |
| Ebitda Margins | 0.066149995 |
| Enterprise To Ebitda | 112.004 |
| Enterprise To Revenue | 7.409 |
| Enterprise Value | 4,698,697,216 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fax | 609 662 2001 |
| Fifty Day Average | 14.403 |
| Fifty Two Week High | 14.5 |
| Fifty Two Week Low | 5.51 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,180,618,200 |
| Float Shares | 311,435,326 |
| Forward Eps | 0.96 |
| Forward P E | 17.694252 |
| Free Cashflow | 47,844,500 |
| Full Time Employees | 511 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.88501 |
| Gross Profits | 561,281,024 |
| Held Percent Insiders | 0.00686 |
| Held Percent Institutions | 1.04389 |
| Implied Shares Outstanding | 314,000,712 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc. |
| Long Name | Amicus Therapeutics Inc |
| Market Cap | 4,549,870,080 |
| Max Age | 86,400 |
| Message Board Id | finmb_7009878 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -27,110,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,549,870,316 |
| Number Of Analyst Opinions | 5 |
| Open | 14.49 |
| Operating Cashflow | 33,145,000 |
| Operating Margins | 0.0861 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 609 662 2000 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 16.42857 |
| Price To Sales Trailing12 Months | 7.174075 |
| Profit Margins | -0.04275 |
| Quick Ratio | 1.719 |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Regular Market Day High | 14.5 |
| Regular Market Day Low | 14.49 |
| Regular Market Open | 14.49 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 5,285,334 |
| Return On Assets | 0.02485 |
| Return On Equity | -0.11578 |
| Revenue Growth | 0.237 |
| Revenue Per Share | 2.057 |
| Sand P52 Week Change | 0.1918689 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 314,000,712 |
| Shares Percent Shares Out | 0.0698 |
| Shares Short | 21,923,629 |
| Shares Short Previous Month Date | 1,773,360,000 |
| Shares Short Prior Month | 20,187,440 |
| Short Name | Amicus Therapeutics, Inc. |
| Short Percent Of Float | 0.070300005 |
| Short Ratio | 6.36 |
| State | NJ |
| Symbol | FOLD |
| Target High Price | 14.5 |
| Target Low Price | 14.5 |
| Target Mean Price | 14.5 |
| Target Median Price | 14.5 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 293,536,000 |
| Total Cash Per Share | 0.935 |
| Total Debt | 442,363,008 |
| Total Revenue | 634,209,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -0.09 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 10.88025 |
| Underlying Symbol | FOLD |
| Uuid | 18ecfd93-9817-3a94-a13a-c6019ef27903 |
| Volume | 5,285,334 |
| Website | https://amicusrx.com |
| Zip | 8,542 |